Show simple item record

dc.contributor.authorOliveira, Guilherme H.*
dc.contributor.authorMukerji, Siddarth*
dc.contributor.authorHernández, Adrian V.*
dc.contributor.authorQattan, Marwan Y.*
dc.contributor.authorBanchs, Jose*
dc.contributor.authorDurand, Jean-Bernard*
dc.contributor.authorIliescu, Cezar*
dc.contributor.authorPlana, Juan Carlos*
dc.contributor.authorTang, W.H. Wilson*
dc.date.accessioned2014-06-10T01:13:06Z
dc.date.available2014-06-10T01:13:06Z
dc.date.issued2014-06-09
dc.identifier.issn0002-9149
dc.identifier.doi10.1016/j.amjcard.2014.03.018
dc.identifier.urihttp://hdl.handle.net/10757/320254es_PE
dc.description.abstractAlthough left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherElsevier B.V.es_PE
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S000291491400808Xes_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.titleIncidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patientses_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.eissn1879-1913
dc.identifier.journalAmerican Journal of Cardiologyes_PE
dc.description.peer-reviewRevisión por pareses_PE
refterms.dateFOA2018-06-19T00:18:01Z
html.description.abstractAlthough left ventricular (LV) dysfunction occurs not uncommonly in the course of cancer therapy, little is known about its natural history and prognostic impact on patients. To investigate the incidence, predictors, and impact on survival of LV systolic dysfunction and recovery during cancer therapy, we conducted a retrospective cohort observational study over 1 year at the University of Texas MD Anderson Cancer Center. We enrolled patients with a decrease in ejection fraction by echocardiography to <50% while undergoing cancer therapy from January 2009 to December 2009.We collected and analyzed their chart data. Of 7,648 patients with echocardiograms in 2009, 366 (4.8%) had ejection fraction <50% and 104 met study criteria. LV systolic dysfunction was associated with cardiotoxic therapy in 53 patients (51%). Recovery occurred in 57 patients (55%) and was independently predicted by younger age, smaller left atrial volume index, and lower B-type natriuretic peptide. At last follow-up, 69 patients (66%) were dead, and 35 (34%) were alive. There was a 20% advantage in 2-year survival among patients with LV systolic recovery compared with those without (95% confidence interval 4% to 41%, p [ 0.02). In this retrospective study, LV systolic dysfunction recovery occurred in over half of the patients, appeared independent of cardiotoxic etiology, and associated with a 20% survival benefit at 2 years. Multivariable predictors of recovery are younger age, a small left atrial volume index, and lower B-type natriuretic peptide.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
AVHernandez AmJCardiol2014.pdf
Size:
429.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record